Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
- Resource Type
- Article
- Source
- In
Clinical and Translational Radiation Oncology February 2019 15:62-69 - Subject
- Language
- ISSN
- 2405-6308